Resultados de procura - Jaroslav Čermák

Limitar resultados
  1. 1
    C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor

    C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor por Jaroslav Čermák, NS Key, RR Bach, József Balla, HS Jacob, GM Vercellotti

    Publicado 1993
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor

    C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor por Jaroslav Čermák, NS Key, RR Bach, József Balla, HS Jacob, GM Vercellotti

    Publicado 1993
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome

    Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome por Michaela Dostálová Merkerová, Zdeněk Krejčík, Hana Votavová, Monika Beličková, Alžběta Vašíková, Jaroslav Čermák

    Publicado 2010
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Differential Expression of MicroRNAs in CD34+ Cells of 5q- Syndrome

    Differential Expression of MicroRNAs in CD34+ Cells of 5q- Syndrome por Hana Votavová, Martina Grmanova, Michaela Dostálová Merkerová, Monika Beličková, Alžběta Vašíková, R Neuwírtová, Jaroslav Čermák

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors

    TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors por Magdalena Plašilová, J Živný, Jaroslav Jelı́nek, R Neuwírtová, Jaroslav Čermák, E Nečas, Ladislav Anděra, Tomáš Stopka

    Publicado 2002
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations

    Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations por Imre Bodó, Ismail Amine, Ana Boban, Horia Bumbea, Alexander Kulagin, Elena Lukina, Agnieszka Piekarska, Irena Preložnik Zupan, Juraj Sokol, Jerzy Windyga, Jaroslav Čermák

    Publicado 2023
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  7. 7
    <i>TP53</i> mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes

    <i>TP53</i> mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes por Monika Beličková, Jitka Veselá, Anna Jonášová, Barbora Pejsova, Hana Votavová, Michaela Dostálová Merkerová, Zuzana Zemanová, Jana Březinová, Dana Mikulenková, Marie Lauermannová, J Válka, K Michalová, R Neuwírtová, Jaroslav Čermák

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient Outcome

    Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient Outcome por Andrea Hruštincová, Zdeněk Krejčík, Dávid Kundrát, Katarína Szikszai, Monika Beličková, Pavla Pecherková, Jǐŕı Kléma, Jitka Veselá, Monika Hruba, Jaroslav Čermák, Tereza Hrdinova, Matyáš Krijt, J Válka, Anna Jonášová, Michaela Dostálová Merkerová

    Publicado 2020
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    BCL11A deletions result in fetal hemoglobin persistence and neurodevelopmental alterations

    BCL11A deletions result in fetal hemoglobin persistence and neurodevelopmental alterations por Anindita Basak, Miroslava Hančárová, Jacob C. Ulirsch, Tuğçe B. Balcı, Marie Trková, Michal Pelisek, Markéta Vlčková, Kateřina Mužíková, Jaroslav Čermák, Jan Trka, David A. Dyment, Stuart H. Orkin, Mark J. Daly, Zdeněk Sedláček, Vijay G. Sankaran

    Publicado 2015
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies

    Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies por Jens Panse, Bing Han, Jaroslav Čermák, Fernando Ataúlfo González Fernández, Akihiko Gotoh, Austin Kulasekararaj, Olena Kyselova, Fahri Şahin, Phillip Scheinberg, Hubert Schrezenmeier, Nicole Straetmans, Yasutaka Ueda, Amy Chang, Brittany Gentile, Jennifer Stefani, Marianne Uguen, Alexander Röth

    Publicado 2025
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

    Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment... por Hagop M. Kantarjian, Xavier Thomas, Anna Dmoszyńska, Agnieszka Wierzbowska, Grzegorz Mazur, Jiří Mayer, Jyh-Pyng Gau, Wen‐Chien Chou, Rena Buckstein, Jaroslav Čermák, Ching-Yuan Kuo, Albert Oriol, Farhad Ravandi, Stefan Faderl, Jacques Delaunay, Daniel Lysák, Mark D. Minden, Christopher Arthur

    Publicado 2012
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  12. 12
    Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories

    Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and... por Michael Pfeilstöcker, Heinz Tuechler, Lionel Adès, Jaroslav Čermák, Fatiha Chermat, Matteo Giovanni Della Porta, Pierre Fenaux, Guillermo Garcia‐Manero, Ulrich Germing, Detlef Haase, Andrea Kuendgen, Michael Luebbert, Sílvia Maria Meira Magalhães, Luca Malcovati, Yasushi Miyazaki, Guillermo Sanz, Valeria Santini, Mikkael A. Sekeres, Matthew J. Walter, Peter Valent, Peter L. Greenberg

    Publicado 2022
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

    Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet por Luca Malcovati, Eva Hellström‐Lindberg, David Bowen, Lionel Adès, Jaroslav Čermák, Consuelo del Cañizo, Matteo Giovanni Della Porta, Pierre Fenaux, Norbert Gattermann, Ulrich Germing, Joop H. Jansen, Moshe Mittelman, Ghulam Mufti, Uwe Platzbecker, Guillermo Sanz, Dominik Selleslag, Mette Skov-Holm, Reinhard Stauder, Argiris Symeonidis, Arjan A. van de Loosdrecht, Théo de Witte, Mario Cazzola

    Publicado 2013
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study

    Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study por Hege Kristin Gravdahl Garelius, Timothy Bagguley, Adele M. Taylor, Pierre Fenaux, David Bowen, Argiris Symeonidis, Moshe Mittelmann, Reinhard Stauder, Jaroslav Čermák, Guillermo Sanz, Saskia Langemeijer, Luca Malcovati, Ulrich Germing, Laurence Sanhès, Maud D’Aveni, Dominic Culligan, Ιoannis Kotsianidis, Karin A. Koinig, Corine van Marrewijk, Simon Crouch, Theo deWitte, Alexandra Smith, Eva Hellström‐Lindberg

    Publicado 2025
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    Validation of the revised international prognostic scoring system (<scp>IPSS</scp>‐R) in patients with lower‐risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet <scp>MDS</scp> (<scp>EUMDS</scp>) registry

    Validation of the revised international prognostic scoring system (<scp>IPSS</scp>‐R) in patients with lower‐risk myelodysplastic syndromes: a report from the prospective European... por Louise de Swart, Alex Smith, W. Thomas Johnston, Detlef Haase, Jackie Droste, Pierre Fenaux, Argiris Symeonidis, Guillermo Sanz, Eva Hellström‐Lindberg, Jaroslav Čermák, Ulrich Germing, Reinhard Stauder, Otilia Georgescu, Marius MacKenzie, Luca Malcovati, Mette Skov Holm, António Almeida, Krzysztof Mądry, Borhane Slama, Agnès Guerci‐Bresler, Laurence Sanhès, Odile Beyne‐Rauzy, Elisa Luño, David Bowen, Théo de Witte

    Publicado 2015
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study

    Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study por Reinhard Stauder, Ge Yu, Karin A. Koinig, Timothy Bagguley, Pierre Fenaux, Argiris Symeonidis, Guillermo Sanz, Jaroslav Čermák, Moshe Mittelman, Eva Hellström‐Lindberg, Saskia Langemeijer, Mette Skov Holm, Krzysztof Mądry, Luca Malcovati, Aurelia Tatic, Ulrich Germing, Aleksandar Savić, Corine van Marrewijk, Agnès Guerci‐Bresler, Elisa Luño, Jackie Droste, Fabio Efficace, Alexandra Smith, David Bowen, Théo de Witte

    Publicado 2018
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  17. 17
    Clonal evolution in myelodysplastic syndromes

    Clonal evolution in myelodysplastic syndromes por Pedro da Silva-Coelho, Leonie I. Kroeze, Kenichi Yoshida, Theresia N. Koorenhof‐Scheele, Ruth Knops, Louis T. van de Locht, Aniek O. de Graaf, Marion Massop, Sarah Sandmann, Martin Dugas, Marian Stevens‐Kroef, Jaroslav Čermák, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Satoru Miyano, Théo de Witte, Nicole M. A. Blijlevens, Petra Muus, Gerwin Huls, Bert A. van der Reijden, Seishi Ogawa, Joop H. Jansen

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  18. 18
    Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes

    Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes por Louise de Swart, Simon Crouch, Marlijn Hoeks, Alex Smith, Saskia Langemeijer, Pierre Fenaux, Argiris Symeonidis, Jaroslav Čermák, Eva Hellström‐Lindberg, Reinhard Stauder, Guillermo Sanz, Moshe Mittelman, Mette Skov Holm, Luca Malcovati, Krzysztof Mądry, Ulrich Germing, Aurelia Tatic, Aleksandar Savić, António Almeida, Njetočka Gredelj-Šimec, Agnès Guerci‐Bresler, Odile Beyne‐Rauzy, Dominic Culligan, Ιoannis Kotsianidis, Raphaël Itzykson, Corine van Marrewijk, Nicole M. A. Blijlevens, David Bowen, Théo de Witte

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  19. 19
    The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

    The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patien... por Andrew H. Wei, Hartmut Döhner, Christopher Pocock, Pau Montesinos, Boris V. Afanasyev, Hervé Dombret, Farhad Ravandi, Hamid Sayar, Jun Ho Jang, Kimmo Porkka, Dominik Selleslag, Irwindeep Sandhu, Mehmet Turgut, Valentina Giai, Yishai Ofran, Merih Kızıl Çakar, Aïda Botelho de Sousa, Justyna Rybka, Chiara Frairia, Lorenza Borin, Germana Beltrami, Jaroslav Čermák, Gert J. Ossenkoppele, Ignazia La Torre, Barry Skikne, Keshava Kumar, Qian Dong, C.L. Beach, Gail J. Roboz

    Publicado 2019
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  20. 20
    Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

    Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission por Andrew H. Wei, Hartmut Döhner, Christopher Pocock, Pau Montesinos, Boris V. Afanasyev, Hervé Dombret, Farhad Ravandi, Hamid Sayar, Jun‐Ho Jang, Kimmo Porkka, Dominik Selleslag, Irwindeep Sandhu, Mehmet Turgut, Valentina Giai, Yishai Ofran, Merih Kızıl Çakar, Aïda Botelho de Sousa, Justyna Rybka, Chiara Frairia, Lorenza Borin, Germana Beltrami, Jaroslav Čermák, Gert J. Ossenkoppele, Ignazia La Torre, Barry Skikne, Keshava Kumar, Qian Dong, C.L. Beach, Gail J. Roboz

    Publicado 2020
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: